Addex Therapeutics (FRA:APE1) FCF Margin %: 0.00% (As of Mar. 2026)


FRA:APE1 Addex Therapeutics Ltd FRA:APE1
7 GF Score
Price €4.90
GF Value €1.12
! 6 Warning Signs
View Full Analysis

What is Addex Therapeutics FCF Margin %?

Addex Therapeutics FRA:APE1 -3.92% 7 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:APE1 with a GF Score™ of 7/100 and a GF Value™ of €1.12. The stock has 6 warning signs investors should review. Among 959 Biotechnology companies, Addex Therapeutics ranks worse than 92.28% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Addex Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was €-0.84 Mil. Addex Therapeutics's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Addex Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Addex Therapeutics's current FCF Yield % is -35.14%.

The historical rank and industry rank for Addex Therapeutics's FCF Margin % or its related term are showing as below:

FRA:APE1' s FCF Margin % Range Over the Past 10 Years
Min: -7884.38   Med: -500.65   Max: 28.84
Current: -7884.38

During the past 13 years, the highest FCF Margin % of Addex Therapeutics was 28.84%. The lowest was -7884.38%. And the median was -500.65%.

FRA:APE1's FCF Margin % is ranked worse than
92.28% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs FRA:APE1: -7884.38

Addex Therapeutics FCF Margin % Related Terms

Addex Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics FCF Margin % Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -505.39 -1,155.93 -495.96 -1,329.56 -7,271.88

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1,781.25 0.00 0.00

FRA:APE1 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Addex Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Addex Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's FCF Margin % falls into.


FRA:APE1
7GF Score
Addex Therapeutics Ltd FRA:APE1
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Addex Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Addex Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-2.327/0.032
=-7,271.88 %

Addex Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.842/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Addex Therapeutics (FRA:APE1) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Addex Therapeutics and its competitors. According to the industry distribution chart, Addex Therapeutics ranks #885 out of 959 companies in the Biotechnology industry, placing it in the top 92.3%.
Is Addex Therapeutics' FCF Margin % too high?
Addex Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Addex Therapeutics ranks #885 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Addex Therapeutics has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Addex Therapeutics' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Addex Therapeutics ranks #885 out of 959 companies for FCF Margin %. This places Addex Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE1) has a current FCF Margin % of 0.00%. The stock's GF Value™ is €1.12, compared to a current price of €4.90 — trading 337.5% above its estimated fair value. The current FCF Margin % is 0.00%. Addex Therapeutics' overall GF Score™ is 7/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE1), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Addex Therapeutics (FRA:APE1) Overvalued in 2026?

Based on GuruFocus' analysis, Addex Therapeutics stock appears to be overvalued. The current stock price of €4.90 is trading 337.5% above its estimated GF Value™ of €1.12.

Key valuation signals for FRA:APE1:

  • FCF Margin %: 0.00%
  • GF Value™: €1.12 vs. price of €4.90 (337.5% above fair value)
  • GF Score™: 7/100 with 6 warning signs

No single metric tells the full story. See the FRA:APE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
7GF Score

Get the complete analysis for FRA:APE1

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.90
Price
€1.12
GF Value